文献速递妇科

外周血p53基因第2~4外显子突变与HPV16型阳性子宫颈癌易感性的相关性及临床意义

[Correlation between mutation of p53 gene 2-4 exons from peripheral blood and HPV16 positive cervical cancer susceptibility and clinical significance].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2017-01-01

该研究纳入2012年10月至2014年4月昆明医科大学第三附属医院167例HPV16型阳性子宫颈癌患者和160例高危型HPV阴性健康妇女,检测外周血p53基因第2~4外显子突变。结果显示各位点等位基因、基因型及单体型频率在两组间均无显著差异(P>0.05),但分层分析发现部分等位基因、基因型及单体型频率与病理类型、分化程度及肌层浸润深度有关。

要点

  • p53基因2~4外显子各突变位点频率在HPV16阳性子宫颈癌组与HPV阴性健康对照组间无显著差异。
  • 鳞癌患者A2等位基因、A1A2基因型、C-A2单体型频率均明显低于非鳞癌患者。
  • 高~中分化患者C等位基因频率明显低于低分化患者,G-A1单体型频率明显增高。

核心结论

  • 外周血p53基因2~4外显子突变与HPV16型阳性子宫颈癌的发生无关,但携带C和A2等位基因、GG和A1A2基因型、C-A2和G-A1单体型的子宫颈癌与低分化、深肌层浸润和病理类型为非鳞癌有关。
  • p53基因多态性分析可为子宫颈癌预后评估及个体化治疗提供一定的依据。

研究设计与样本

  • 选取2012年10月至2014年4月昆明医科大学第三附属医院收治的经HPV分型检测及病理检查证实为HPV16型阳性的子宫颈癌患者167例为子宫颈癌组,以同期门诊体检的高危型HPV阴性健康妇女160例为对照组。
  • 取外周静脉血提取基因组DNA,经PCR扩增及双向测序法检测后使用DNAstar软件分析两组妇女外周血p53基因2~4外显子突变情况,并对不同临床病理特征的子宫颈癌患者各突变位点的等位基因、基因型、单体型频率进行比较。

主要发现

  • p53基因2~4外显子区存在3个突变位点和1个插入或缺失片段:第2内含子区SNP11827位点C/G突变、第3内含子区SNP11992位点A/C突变、第4外显子区第72密码子rs1042522位点C/G突变以及第3内含子区rs17878362位点16 bp重复插入或缺失(acctggagggctgggg,缺失记为A1、插入记为A2)。
  • 各位点等位基因、基因型频率及单体型频率在子宫颈癌组与对照组间比较均无显著差异(P>0.05)。
  • 鳞癌患者A2等位基因频率[3.5%(10/284)]低于非鳞癌患者[11.8%(4/34)](χ²=4.90,P=0.027),A1A2基因型频率[7.0%(10/142)]低于非鳞癌患者[4/17](χ²=5.14,P=0.023),C-A2单体型频率[3.5%(10/284)]低于非鳞癌患者[11.8%(4/34)](χ²=4.91,P=0.027)。
  • 高~中分化患者SNP11827、rs1042522位点C等位基因频率[38.8%(62/160)]低于低分化患者[50.8%(61/120)](χ²=4.07,P=0.044),G-A1单体型频率[61.2%(98/160)]高于低分化患者[49.2%(59/120)](χ²=4.07,P=0.044)。
  • 浅肌层浸润患者SNP11827、rs1042522位点GG基因型频率[21.1%(8/38)]低于深肌层浸润患者[46.3%(25/54)](χ²=7.06,P=0.029)。

临床怎么用

  • 作者认为,p53基因多态性分析可为子宫颈癌预后评估及个体化治疗提供一定的依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To detect mutations of p53 gene 2-4 exons from peripheral blood and to explore their relevance in HPV16-positive cervical cancer susceptibility and clinical significance. Methods: Collected firstly cases from the Third Affiliated Hospital of Kunming Medical University from October 2012 to April 2014, included 167 cases HPV16-postive cervical cancer and 160 cases HPV-negative healthy women. Genomic DNA from the host peripheral venous blood was taken, mutations of p53 gene 2-4 exons were analyzed with software DNAstar after PCR and bidirectional sequencing. Meanwhile, mutations of p53 gene 2-4 exons among different clinicopathological characteristics in HPV16-postive cervical cancer were distinguished. Results: (1) Three mutations and an 16-bp insertion/deletion sequences were found in p53 gene exons 2-4, included C/G mutation of single nucleotide polymorphism (SNP) 11827 in intron2, A/C mutation of SNP11992 in intron3, C/G mutation in codon 72 (rs1042522) of exon4 and 16-bp (acctggagggctgggg) repeat insertion or deletion in intron3 (rs17878362), while deletion recorded as A1, insertion recorded as A2. No significant differences were found in each point allele and genotype frequency (P>0.05) . (2) Stratified analysis for cervical cancer group resulted with some differences. Compared group of non-squamous carcinoma with squamous carcinoma group, there were obviously decreased in allete A2 [11.8% (4/34) vs 3.5% (10/284) ; χ(2)=4.90, P=0.027], genotype A1A2 [4/17 vs 7.0% (10/142) ; χ(2)=5.14, P=0.023], and haplotype C-A2 [11.8% (4/34) vs 3.5% (10/284) ; χ(2)=4.91, P=0.027]. Compared with poorly differentiated group, allele C of SNP11827 and rs1042522 were obviously decreased in medium high differentiation group [50.8% (61/120) vs 38.8% (62/160) ; χ(2)=4.07, P=0.044], while haplotype G-A1 were apparently higher [49.2% (59/120) vs 61.2% (98/160) ; χ(2)=4.07, P=0.044], genotype GG of SNP11827 and rs1042522 were obviously decreased in superficial myometrial invasion depth group than that in deep myometrial invasion depth group [46.3% (25/54) vs 21.1% (8/38) ; χ(2)=7.06, P=0.029]. No significant differences were found between stage Ⅰ and Ⅱ, pelvic lymph node metastasis or not (all P>0.05) . Conclusions: No obvious correlation is found between polymorphisms in exons 2-4 of p53 gene and susceptibility of HPV16-postive cervical cancer. But the patient with allete C and A2, genotype GG and A1A2, haplotype C-A2 and G-A1 may be increase risk of poorly differentiation, deep muscular invasion and bad pathological type. Analysis of p53 gene polymorphism may be provide a basis for the prognosis evaluation and individualized treatment of cervical cancer. 目的: 探讨外周血p53基因第2~4外显子突变与HPV16型阳性子宫颈癌易感性的关系及其意义。 方法: 选取2012年10月至2014年4月昆明医科大学第三附属医院收治的经HPV分型检测及病理检查证实为HPV16型阳性的子宫颈癌患者167例(子宫颈癌组),以同期在门诊体检的高危型HPV阴性的健康妇女160例为对照组。取外周静脉血提取基因组DNA,经PCR扩增及双向测序法检测后使用DNAstar软件分析两组妇女外周血p53基因2~4外显子的突变情况,并对不同临床病理特征的子宫颈癌患者外周血p53基因2~4外显子各突变位点的等位基因、基因型、单体型(即指rs1042522/rs17878362位点单体型,包括C-A1、C-A2、G-A1、G-A2)频率进行比较。 结果: (1)双向测序法检测并经DNAstar软件分析后显示,p53基因2~4外显子区存在3个突变位点和1个插入或缺失片段,分别为第2内含子区SNP11827位点C/G突变、第3内含子区SNP11992位点A/C突变、第4外显子区第72密码子rs1042522位点C/G突变以及第3内含子区rs17878362位点16 bp处的重复插入或缺失(acctggagggctgggg,其中缺失记为A1、插入记为A2)。各位点的等位基因、基因型频率及单体型频率在两组妇女间比较均无显著差异(P>0.05)。(2)对子宫颈癌患者的不同临床病理特征进一步进行分层分析,结果显示,与非鳞癌患者比较,鳞癌患者的A2等位基因频率[分别为11.8%(4/34)、3.5%(10/284);χ(2)=4.90,P=0.027]、A1A2基因型频率[分别为4/17、7.0%(10/142);χ(2)=5.14,P=0.023]、C-A2单体型频率[分别为11.8%(4/34)、3.5%(10/284);χ(2)=4.91,P=0.027]均明显降低;与低分化患者比较,高~中分化患者的SNP11827、rs1042522位点的C等位基因频率[分别为50.8%(61/120)、38.8%(62/160);χ(2)=4.07,P=0.044]明显降低,而G-A1单体型频率[分别为49.2%(59/120)、61.2%(98/160);χ(2)=4.07,P=0.044]明显增高;与深肌层浸润患者比较,浅肌层浸润患者的SNP11827、rs1042522位点的GG基因型频率[分别为46.3%(25/54)、21.1%(8/38);χ(2)=7.06,P=0.029]明显降低;各等位基因、基因型、单体型频率在临床分期为Ⅰ期与Ⅱ期、有无盆腔淋巴结转移患者间分别比较,差异均无统计学意义(P>0.05)。 结论: 外周血中p53基因2~4外显子突变与HPV16型阳性子宫颈癌的发生无关,但携带突变位点的C和A2等位基因、GG和A1A2基因型、C-A2和G-A1单体型的子宫颈癌与其低分化、深肌层浸润和病理类型为非鳞癌有关。p53基因多态性分析可为子宫颈癌预后评估及个体化治疗提供一定的依据。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yin CM, Yao YF, Yan ZL, et al. [Correlation between mutation of p53 gene 2-4 exons from peripheral blood and HPV16 positive cervical cancer susceptibility and clinical significance]. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 28545270. doi:10.3760/cma.j.issn.0529-567X.2017.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。